Veliflapon
Alternative Names: DG-031Latest Information Update: 30 Jan 2013
At a glance
- Originator Bayer
- Developer deCODE genetics
- Class Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action 5-lipoxygenase-activating protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Myocardial infarction
Most Recent Events
- 31 Dec 2012 deCODE genetics has been acquired by Amgen
- 12 Mar 2008 Veliflapon is available for licensing (http://www.decode.com)
- 05 Oct 2006 Suspended - Phase-III for Myocardial infarction in Europe (PO)